Anticancer Therapies – News and Features

Company announces positive preliminary results from its ongoing randomized Phase 2 clinical trial in patients with metastatic colorectal cancer.

The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.

ImClone Systems and BMS presents Phase 3 study results at American Society of Clinical Oncology Annual Meeting.

Horizon will be a founding member of VIMCAD, a consortium of UK Oncology research groups, funded by Cancer Research UK.

Sixteen patients have completed dosing of CG0070 administered once weekly or once every four weeks at the two lowest of three doses being evaluated.

The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.

Cytopia has out-licensed technology to Cancer Therapeutics for an undisclosed kinase enzyme target with potential for treating metastatic cancers.

As part of the agreement, ImClone will utilize Champions Biotechnology's Biomerk Tumorgrafts™ in the initial preclinical evaluation.

ACT Biotech acquires an anti-angiogenic receptor tyrosine kinase inhibitor entering Phase II clinical studies for colorectal cancer.

The Phase 2 clinical trial will evaluate picoplatin combination chemotherapy for the first-line treatment of metastatic colorectal cancer.